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Abstract
Background: Fibroblast growth factor-19 (FGF19) is an intestinal hormone that mediates postprandial metabolic
responses in the liver. The unusual orphan nuclear receptor, small heterodimer partner (SHP), acts as a co-repressor
for many transcriptional factors and has been implicated in diverse biological pathways including FGF19-mediated
repression of bile acid synthesis. To explore global functions of SHP in mediating FGF19 action, we identify
genome-wide SHP binding sites in hepatic chromatin in mice treated with vehicle or FGF19 by ChIP-seq analysis.
Results: The overall pattern of SHP binding sites between these two groups is similar, but SHP binding is enhanced
at the sites by addition of FGF19. SHP binding is detected preferentially in promoter regions that are enriched in
motifs for unexpected non-nuclear receptors. We observe global co-localization of SHP sites with published sites for
SREBP-2, a master transcriptional activator of cholesterol biosynthesis. FGF19 increases functional interaction
between endogenous SHP and SREBP-2 and inhibits SREBP-2 target genes, and these effects were blunted in
SHP-knockout mice. Furthermore, FGF19-induced phosphorylation of SHP at Thr-55 is shown to be important for its
functional interaction with SREBP-2 and reduction of liver/serum cholesterol levels.
Conclusion: This study reveals SHP as a global transcriptional partner of SREBP-2 in regulation of sterol biosynthetic
gene networks and provides a potential mechanism for cholesterol-lowering action of FGF19.
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Background
Small heterodimer partner (SHP, NR0B2) is an unusual
orphan nuclear receptor that lacks a DNA binding do-
main and acts as a co-repressor for many other nuclear
receptors involved in diverse biological pathways [1–4].
Recent studies using genetic mouse models have shown
that SHP has a functional role in regulation of lipid/glu-
cose metabolism, circadian control of metabolism,
reproduction, and inflammation [5–9]. Of known SHP
functions, the role of SHP in feedback repression of bile
acid (BA) biosynthesis has been most intensively studied
[5, 6, 10]. An endogenous ligand for SHP has not been
identified, but protein levels and repression activity of
SHP are modulated by post-translational modifications
(PTMs) in response to BA or fibroblast growth factor-19
(FGF19) signaling [11–13]. FGF19 (FGF15 in mice) is an
intestinal hormone that is induced by the BA-activated
nuclear receptor FXR in response to a meal and strongly
represses BA synthetic genes in a SHP-dependent manner
[14, 15]. Intriguingly, the metabolic action of FGF19 is
similar to insulin but FGF19 does not stimulate hepatic
lipogenesis [15]. FGF19 also has cholesterol-lowering ef-
fects [16], but the underlying mechanisms are not known.
Sterol regulatory element-binding proteins (SREBPs)
are a family of basic-helix-loop-helix transcription factors
that regulate lipid metabolism [17]. Of the three mamma-
lian isoforms, SREBP-1c mediates insulin-dependent
activation of fatty acid synthesis, SREBP-2 is a master
* Correspondence: jianma@illinois.edu; jongsook@illinois.edu
†Equal contributors
2Department of Bioengineering, University of Illinois at Urbana-Champaign,
Urbana, IL 61801, USA
1Department of Molecular and Integrative Physiology, University of Illinois at
Urbana-Champaign, Urbana, IL 61801, USA
Full list of author information is available at the end of the article
© 2015 Kim et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. Genome Biology  (2015) 16:268 
DOI 10.1186/s13059-015-0835-6
transcriptional activator of cholesterol biosynthesis,
and SREBP-1a activates both fat and sterol biosyn-
thetic gene programs [18, 19]. SREBP precursors are
retained in the endoplasmic reticulum in a complex
with INSIG and sterol-sensing SCAP. When cellular
sterol levels are low, the complex dissociates and
SREBP/SCAP are transported to the Golgi apparatus,
SREBP is proteolytically cleaved, and the N-terminal
SREBP fragment translocates to the nucleus and acti-
vates expression of fat and cholesterol biosynthetic
genes [17]. A global role of SREBP-2 in lipid metabol-
ism, as well as a new function, autophagy of lipid
droplets under sterol-depleted conditions, was demon-
strated by ChIP-seq studies [20].
In this study, we have identified genome-wide hepatic
binding sites of SHP by ChIP-seq analysis in mice
treated with vehicle or FGF19. SHP binding strikingly
overlapped globally with SREBP-2 binding, published
previously [20], at many sterol biosynthetic genes, includ-
ing the HMG CoA Reductase (Hmgcr) gene. Utilizing mo-
lecular/biochemical approaches and SHP-knockout (KO)
mice [5], we further show that treatment with FGF19 or
feeding, which induces intestinal synthesis of FGF15 in
mice, increases both the functional interaction of endogen-
ous SHP with SREBP-2 in hepatocytes and the inhibition
of sterol biosynthesis-related genes in a SHP-dependent
manner.
Results
Identification of genome-wide binding sites of SHP in
hepatic chromatin in mice
We have identified genome-wide binding sites of SHP
in hepatic chromatin by ChIP-seq analysis in mice
treated with vehicle or FGF19. The quality of the im-
munoprecipitation with SHP antibody was first con-
firmed by standard ChIP to detect binding of SHP at
its known target genes, Cyp7a1, Cyp8b1, Ntcp, in WT
and SHP-KO mice (Additional file 1: Figure S1a).
Samples from three independent ChIP from mouse liver
were pooled for the ChIP-seq sequencing (Additional file 1:
Figure S1b).
A total of 1,508 and 3,154 peaks were detected in the
vehicle-treated and FGF19 samples, respectively, with
686 peaks (at least 1 bp overlap) common to both, and
1,307 and 2,768 genes nearest to the peaks within 50 Kb
were identified for the vehicle- and FGF19-treated sam-
ples, respectively, with 650 genes common to both
(Fig. 1a). Notably, SHP binding peaks were preferentially
in the promoter regions with 66 % and 74 % of peaks
within 1 kb of transcription start sites (TSS) in mice
treated with vehicle and FGF19, respectively (Fig. 1b, c).
This analysis revealed a strong preference of SHP binding
in the proximal promoter regions of potential SHP target
genes in both groups.
De novo motif analysis of SHP binding peak regions
To identify possible transcription factors that recruit SHP
to its sites, DNA motifs were detected by de novo motif
analysis within the SHP binding peak regions (+/- 100 bp
of peak summit). The transcription factor motifs for
previously unknown SHP partners, such as, SP1,
YY1/SREBP-2, EGR1, NF-Y, RUNX2, and NRF1, were
identified within SHP binding peaks (Fig. 1d). Since
these transcription factors commonly bind to prox-
imal promoter regions, further studies will be re-
quired to determine if these factors functionally
interact with SHP or are coincidentally located within
SHP binding areas.
SHP has been shown to directly interact with and in-
hibit many other nuclear receptors, but binding motifs
for known SHP-interacting nuclear receptors, such as
HNF-4, LXR, PPARγ, ROR, RAR, NURR, and RXRα,
were detected only at lower significance than the unex-
pected non-nuclear receptor binding motifs in both ve-
hicle- and FGF19-treated groups (Fig. 2). These results
suggest that in addition to nuclear receptors, SHP may
functionally interact with non-nuclear receptor tran-
scription factors that were not previously recognized as
transcriptional partners.
Functional gene ontology (GO) analysis
To explore biological pathways potentially regulated by
SHP, genes nearest to SHP binding peaks were assigned
to functional groups by GO analysis. In both groups, the
majority of potential SHP target genes were, as expected,
present in metabolic pathways (Fig. 3a). In addition to
metabolic processes, previously unknown functions were
also predicted, which include stress response, signal
transduction, chromatin organization, and regulation of
transcription. Potential SHP target genes that are
uniquely detected in the vehicle-treated sample included
genes involved in drug metabolism, the immune process,
DNA recombination, and circadian rhythm. Some po-
tential SHP target genes that are uniquely detected in
FGF19-treated samples included protein modifications,
in particular ubiquitination, developmental process, hyp-
oxia, autophagy, and 1-carbon metabolism (Fig. 3a).
Overall, this GO analysis suggests that SHP may have a
broader range of biological functions than previously
recognized.
Randomly chosen genes with enriched binding in the
FGF19 group were analyzed by ChIP to validate the
ChIP-seq results. Nearly all of the tested genes, 20 out of
21, showed at least a 1.5-fold increase in SHP binding
after FGF19 treatment (Additional file 1: Figure S2).
SHP binding peaks detected at hepatic genes involved in
selected diverse biological pathways, including BA biosyn-
thesis and transport, are displayed (Fig. 3b, Additional
file 1: Figure S3). SHP was shown to be required for
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FGF15/19-mediated repression of Cyp7a1 [14] but re-
cent tissue-specific genetic mouse studies have indi-
cated that both FGF15 and SHP play important roles in
Cyp8b1 repression, whereas FGF15, but not SHP, prefer-
entially represses Cyp7a1 gene expression [21]. In line
with these recent findings, SHP binding peaks were
readily detected at the promoter of Cyp8b1 gene and
relatively smaller peaks were present at the Cyp7a1 gene
in FGF19-treated sample (Additional file 1: Figure S3).
In standard ChIP assays, FGF19 treatment led to more
marked binding of SHP to the Cyp8b1 promoter com-
pared to Cyp7a1 (Additional file 1: Figure S1a).
Striking global co-occupancy of SHP with SREBP-2 at
hepatic genomes
The DNA motif, AAgATGGCggcg, which was detected
in SHP peak regions (Fig. 1d), binds YY1 but was also
identified as an SREBP-2 motif [20]. In addition, DNA
motifs for SP1 and NF-Y that function synergistically
with SREBPs [22] were detected in SHP binding peak re-
gions (Fig. 1d). SREBP-2 is a master transcription activator
of cholesterol biosynthesis [17], so the possibility that SHP
interacts with SREBP-2 to regulate sterol biosynthesis, in
addition to its role in sterol catabolism into BAs, was
intriguing.
Fig. 1 Genomic distribution of hepatic SHP binding and motif analysis of SHP binding regions. a Venn diagrams showing the numbers of SHP
binding peaks in hepatic chromatin and nearby genes (parentheses) in mice treated with vehicle or FGF19 for 2 h. b Distances from the center of
SHP binding peaks to the TSS. c Genomic distribution of SHP binding peaks in the vehicle- or FGF19-treated group. d Logos showing the
common sequences detected with highest confidence (E-value) at the SHP binding peak regions. For each common sequence motif, up to the
top three transcription factors that potentially bind to the motif are shown
Kim et al. Genome Biology  (2015) 16:268 Page 3 of 14
Remarkably, about 42 % of the SREBP-2 sites, published
previously [20], overlapped with SHP sites (P value <2.2e-
16, Fisher’s exact test) and about 20 % of the SHP sites
overlapped with SREBP-2 sites (Fig. 4a, b). Re-analysis of
the sequence data for the published SREBP-2 ChIP-seq
study using the same pipeline as used for our SHP CHIP-
seq data resulted in about half as many SREBP-2 sites, but
a similar percentage of SREBP-2 sites overlapped with
SHP sites (data not shown).
Since the role of SREBP-2 in regulating the sterol bio-
synthetic pathway is well known, we compared binding
of SHP and SREBP-2 near to genes in this pathway.
Strikingly, SREBP-2 binding coincident with SHP bind-
ing was detected at genes related with sterol biosyn-
thesis, including the rate-limiting enzyme HMGCR, a
master transcription activator, SREBP-2, and its partner
proteins, INSIG and SCAP (Fig. 4c, Additional file 1:
Figure S3). In GO analysis of genes with overlapping
peaks for SHP and SREBP-2, a number of pathways re-
lated with metabolic processes were enriched (Additional
file 1: Figure S4). These genomic analyses suggest a poten-
tial partnership of SHP and SREBP-2 in regulation of
sterol biosynthetic genes in the liver.
SHP is recruited to SREBP-2 target sterol biosynthesis-
related genes and inhibits their expression
We next examined the effect of FGF19 on the occu-
pancy of SHP and SREBP-2 at cholesterol biosynthesis-
related genes. Occupancy of SHP was increased, while
occupancy of SREBP2 was detected but not increased,
by FGF19 at nearly all genes tested in WT mouse liver
(Fig. 5a, b) and in primary mouse hepatocytes and in-
creased SHP binding was not detected in SHP-KO mice
(Additional file 1: Figure S5a, b). Consistent with the co-
repressor function of SHP [13, 23, 24], increased occu-
pancy correlated with decreased mRNA levels by FGF19
treatment (Fig. 5c). FGF19 inhibition of expression of
these genes was not observed in SHP-KO mice (Fig. 5d)
and protein levels of the rate-limiting enzyme for sterol
biosynthetic pathway, HMGCR, was also decreased by
Fig. 2 Motif enrichment in peak regions versus randomly selected background sequences. a, b For each transcription factor, the percentage of
SHP peak regions in vehicle (Veh)- (a) or FGF19-treated samples (b) with motifs within +/-100 bp of the peak summits (peak) or the percentage in
randomly selected sequences (bg) is shown. Randomly selected sequences are GC normalized to the peak region sequences. ‘Non-nuclear
receptor (non-NR)’ binding motifs are for factors that are not in the nuclear receptor superfamily and ‘nuclear receptor (NR)’ motifs are all known
nuclear receptor motifs listed in the JASPAR database. Motifs are ordered on the X-axis from smallest P value to largest P value from left to right
based on the binomial test. ***P <1e-10, **P <0.01, *P <0.1. Note that with exception of PPARγ/RXRα in vehicle-treated sample, none of the
nuclear receptor motifs has a P value smaller than 0.01
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FGF19 in a SHP-dependent manner (Fig. 5e). These re-
sults suggest that SHP is recruited to SREBP-2 target
genes related with cholesterol biosynthesis and inhibits
these genes.
FGF19 increased the functional interaction between SHP
and SREBP-2 at Hmgcr, resulting in epigenomic repression
To test the effect of SHP on SREBP-2 activity, DNA re-
gions of Hmgcr, Insig-1, and Srebp-2 containing both
SHP and SREBP-2 binding sites, were cloned into lucifer-
ase plasmids for reporter assays. Expression of SREBP-2
increased luciferase activities, and co-expression of SHP
inhibited the increased transactivation, while downregula-
tion of SHP enhanced the increase (Fig. 6a). These results
suggest that SHP inhibits SREBP-2 activation of these
genes.
To further examine the effect of FGF19 on SHP regu-
lation of SREBP-2 activity, we performed CoIP protein
interaction studies. FGF19 treatment increased the inter-
action of adenovirally expressed SHP with SREBP-2 in
liver extracts (Fig. 6b). In GST pull-down studies using
partially purified proteins (Additional file 1: Figure S6),
full length SREBP-2 and its central domain fragment
(50-330 aa) bound to SHP, while full length SHP and its
N-terminal domain (1-92 aa) bound to SREBP-2 (Fig. 6c),
indicating that SHP and SREBP-2 directly interact.
FGF19 treatment increased nuclear localization of
SHP in the nucleus (Fig. 6d). This observation together
with the observations of direct interaction between SHP
and SREBP-2, which was increased interaction by FGF19,
suggests that SREBP-2 may recruit SHP to its target chol-
esterol biosynthetic genes and that these two proteins co-
occupy the same genomic site in these genes. We, thus,
examined these possibilities using Hmgcr gene as a model
by re-ChIP assays. In chromatin first precipitated by
SREBP-2 antibody, Hmgcr sequence enriched by re-
precipitation with SHP antibody was increased by FGF19
(Fig. 6e). Since occupancy of SREBP-2 at Hmgcr was not
increased by FGF19 (Fig. 5b), these results suggest that
SREBP-2 binds constitutively to Hmgcr and recruits SHP
to the gene upon FGF19 treatment. Increased SHP occu-
pancy at Hmgcr, Insig-1, and Srebp-2 by FGF19 treatment
was nearly abolished when SREBP-2 was downregulated
in hepatocytes (Fig. 6f), indicating that SHP occupancy is
dependent on SREBP-2.
SHP inhibits its target genes by recruiting repressive
histone modifiers, such as HDACs and LSD1, resulting
in epigenomic repression [23–25]. As expected, occu-
pancy of LSD1 and HDAC1/3 was increased by FGF19
(Fig. 6g), and levels of H3K4-me3 and H3K9/14-Ac,
gene activation histone markers [26], were decreased by
FGF19 but these effects were attenuated in SHP-KO
Fig. 3 GO analysis and display of SHP binding peaks. a Categories (from the top 500 GO annotations) of the potential SHP target genes (nearest
to and within 50 Kb of SHP binding peaks using GREAT) detected for both groups and uniquely in each group. b Normalized SHP binding peaks
at hepatic genes involved in diverse biological pathways are displayed (UCSC genome browser)
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mice (Fig. 6h). As illustrated in Fig. 6i, these results sug-
gest that SHP is recruited to SREBP2-bound chromatin
at sterol biosynthetic genes by FGF19 treatment, result-
ing in epigenomic repression.
Feeding inhibited SREBP-2 target sterol biosynthetic
genes in a SHP-dependent manner
After a meal, FGF15/19 is induced by BA-activated FXR
in the ileum and acts at the liver to mediate postprandial
responses [14, 15]. In humans, serum FGF19 levels were
shown to be elevated about 3 h after feeding long after
insulin levels are increased [27]. We, therefore, exam-
ined the effects of feeding, which would activate en-
dogenous FGF15 signaling by BA-activated intestinal
FXR on the functional interaction of endogenous SHP
and SREBP-2.
Increased levels of phosphorylated ERK, a marker of







Fig. 4 Co-localization of SHP and SREBP-2 binding sites in hepatic genomes. a A Venn diagram showing the overlap between the binding peaks
of SHP and SREBP-2 [20] in hepatic chromatin. Peaks with at least 1 bp overlap were designated as overlapping. b Heat map analysis showing
overlapping binding peaks of SHP and SREBP-2 in vehicle- or FGF19-treated group (SHP SREBP2 overlapping); SHP peaks present in both groups
(SHP conserved); and peaks present in only one group as indicated (predominant). c Normalized ChIP-seq peaks for SHP and SREBP-2 at selected
sterol biosynthetic networks are displayed (UCSC genome browser)
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fed for 6 h after 12 h of fasting (Fig. 7a). In cellular frac-
tionation studies, feeding increased nuclear abundance
of SHP, but SREBP-2 was constitutively localized in the
nucleus (Fig. 7b). Importantly, the interaction in liver
nuclear extracts between endogenous SHP and SREBP-2
was increased by feeding (Fig. 7c). In ChIP assays, feed-
ing decreased levels of gene activation histone marks,
H3K4-me3 and H3K9/14-Ac, at Hmgcr gene in WT
mice, but these effects were diminished in SHP-KO mice
(Fig. 7d). Feeding also inhibited expression of direct
SREBP-2 target sterol biosynthesis-related genes (Fig. 7e)
and significantly decreased HMGCR protein levels in
WT mice (Fig. 7f ). In sharp contrast, in SHP-KO mice,
basal expression of these genes in fasted mice was highly
elevated and was not decreased by feeding nor were
HMGCR protein levels decreased. Treatment with an
FXR agonist, GW4064, which would result in intestinal
induction of endogenous FGF15, also decreased expres-
sion of these genes similar to those treated with FGF19
or feeding (Fig. 7g). These results suggest that the func-
tional interaction between endogenous SHP and SREBP-
2 is increased in the nucleus physiologically by feeding
and that SHP is important for feeding-mediated in-
hibition of SREBP-2 target genes involved in sterol
biosynthesis.
FGF19-induced phosphorylation of SHP at Thr-55 is
important for inhibition of sterol biosynthetic genes and
reducing cholesterol levels
An important question is how SHP senses the FGF19
signal to mediate transcriptional responses. It was shown
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Fig. 5 SHP was recruited to SREBP-2 target sterol biosynthesis-related genes and inhibits their expression. Mice were treated with vehicle or
FGF19 and livers were pooled from three mice for ChIP assays (a, b) to examine occupancy of SHP (a) and SREBP-2 (b) at the indicated genes,
and mRNA levels of genes near SHP binding peaks (c). Statistical significance was determined by the Student’s t-test (SEM, n = 3, *P <0.05,
**P <0.01). d, e WT or SHP-KO mice were treated with vehicle or FGF19 for 6 h and livers were collected. d Effects of FGF19 on mRNA levels of
indicated genes. e Hepatic protein levels of HMGCR in WT and SHP-KO mice were measured and relative HMGCR levels are shown (right)
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Fig. 6 (See legend on next page.)
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FGF19 signaling [13]. To test if this phosphorylation of
SHP at Thr-55 is important for inhibition of SREBP-2
transactivation by FGF19, we examined the effects of
mutation of Thr-55 on expression of Hmgcr, Insig, and
Srebp-2 genes using luciferase reporter plasmids con-
taining the promoter regions of these genes that bound
both SHP with SREBP-2. Expression of SREBP-2 in-
creased the luciferase activity and overexpression of SHP
wild type (WT) decreased the activity in a dose-
dependent manner (Fig. 8a). In contrast, these effects
were not observed with the phosphorylation-defective
T55A mutant and notably, the T55A mutant acted like a
dominant negative mutant and increased expression.
These data suggest that FGF19-induced Thr-55 phos-
phorylation of SHP is important for its inhibition of
SREBP-2 activity.
To determine the role of phosphorylation of SHP on
functional interaction with SREBP-2 in the liver, mice
were tail vein injected with adenovirus expressing SHP
WT or T55A and 1 week later, the mice were treated
with FGF19 for 2 h (Fig. 8b). The protein levels of SHP
in adenoviral-mediated expression groups were similar
to physiological levels of SHP after BA-mediated induc-
tion (Fig. 8c). In CoIP studies, the increased interaction
of SHP with SREBP-2 by FGF19 was markedly dimin-
ished with the T55A mutant compared to control WT
(Fig. 8d). In ChIP assays, the increased SHP occupancy
at selected SREBP-2 target genes by FGF19 treatment
was not observed with the T55A mutant (Fig. 8e). These
results suggest a potential role of FGF19-induced phos-
phorylation of SHP in functional interaction with
SREBP-2 in the nucleus.
Finally, we determined the effects of mutation of Thr-
55 on expression of key sterol biosynthetic genes and
serum/liver cholesterol levels. Adenoviral-mediated
liver-specific expression of SHP WT (Fig. 8f ) resulted in
decreased mRNA levels of nearly all tested genes but
these effects were completely blocked in mice expressing
the phosphorylation-defective Thr-55 SHP mutant
(Fig. 8g). As expected from the increased expression of
cholesterol biosynthetic genes, levels of cholesterol in
liver and serum were significantly increased in mice ex-
pressing the Thr-55A SHP mutant (Fig. 8h). These stud-
ies suggest that FGF19-induced phosphorylation of SHP
at Thr-55 is important for its functional interaction with
SREBP-2 and inhibition of SREBP-2 target genes related
with the sterol biosynthetic pathway.
Discussion
We have identified genome-wide binding sites of SHP in
hepatic chromatin and demonstrate that SHP is a new
transcriptional partner with SREBP-2 in the regulation
of cholesterol biosynthesis. The ChIP-seq analysis re-
vealed 1,508 and 3,155 binding sites in vehicle- and
FGF19-treated groups, respectively, with about 685 sites
present in both groups. The overall pattern of SHP bind-
ing between these two groups was similar but SHP bind-
ing was enhanced at the sites by FGF19. Remarkably,
SHP binding peaks in both groups showed a strong prefer-
ence for the promoter regions, which provides confidence
that the binding is functionally significant. Potential new
functions directly regulated by SHP were identified and
unexpected motifs for non-nuclear receptor transcription
factors that are enriched in SHP binding regions were also
identified.
A striking finding is that SHP acts as a global partner
with SREBP-2 in regulation of cholesterol biosynthesis.
A remarkable global overlapping of many SHP binding
sites with those of SREBP-2, previously published [20],
was detected. Over 40 % of the SREBP-2 sites co-
localized with SHP sites and about 20 % of the SHP sites
were co-localized with SREBP-2 sites. Remarkably, SHP
binding was detected at most of SREBP-2 target genes
related with sterol biosynthesis, including Hmgcr. We
showed that endogenous SHP interacts with SREBP-2 in
response to FGF19 or feeding, is recruited to direct
SREBP-2 target sterol biosynthetic genes, and inhibits
their expression (Fig. 9). We further showed that FGF19
signal-induced phosphorylation of SHP at Thr-55 ap-
pears to be important for functional interaction with
(See figure on previous page.)
Fig. 6 FGF19 increased functional interaction of SHP with SREBP-2, resulting in epigenomic repression. a Reporter assay: HepG2 cells were trans-
fected with plasmids and infected with adenoviruses as indicated, treated with FGF19, and luciferase activity was normalized to β-galactosidase
activity. Protein levels of SHP are shown at right. b CoIP: Mice were tail vein injected with Ad-flag-SHP, 1 week after infection, mice were treated
with vehicle or FGF19 for 2 h, and CoIP assays using liver nuclear extracts were performed. P or M indicates the precursor or mature form of
SREBP-2, respectively. c GST pull-down: Schematics of the SHP and SREBP-2 domains fused to GST are shown at the top. The amount of SHP and
SREBP-2 bound to the reciprocal GST-proteins were determined by IB. d Fractionation study: Effects of FGF19 on protein levels of SHP and SREBP-
2 in nuclear and cytoplasmic fractions of mouse liver extracts. Actin and lamin were markers for the cytoplasm and nucleus, respectively. e Liver
re-ChIP: Mice were treated with vehicle or FGF19 for 2 h and livers were pooled from three mice. Chromatin was immunoprecipitated with
SREBP-2 antibody first and then eluted and re-precipitated with SHP antibody. f siRNA/ChIP: Hepatocytes were transfected with siRNA for SREBP-2
or control RNA and then 3 days later, cells were treated with vehicle or FGF19 for 2 h and ChIP assays were done. Statistical significance was
determined by the Student’s t-test (SEM, n = 3, *P <0.05). At right, levels of nuclear SREBP-2 protein levels detected by IB are shown. g, h ChIP: WT
or SHP-KO mice (pooled from three mice) were treated with vehicle or FGF19 and ChIP assays were done. i Model illustrating molecular mechanisms
by which SHP inhibits SREBP-2 direct target genes
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SREBP-2 in the nucleus. These molecular and biochemical
studies, together with genomic analyses, demonstrate that
SHP and SREBP-2 are transcriptional partners in the
regulation of cholesterol biosynthesis gene networks in
response to FGF19.
The functional role of SHP in the inhibition of the
conversion of cholesterol to BAs to reduce liver BA
levels and prevent hepatotoxicity has been established
[5, 6, 10], but the consequential increase in cholesterol
levels could detrimentally result in hypercholesterolemia
and related diseases. Our present study suggests that
SHP, with SREBP-2, inhibits expression of hepatic genes
involved in sterol biosynthesis and regulatory processes,
which would likely counteract the inhibition of choles-
terol catabolism and prevent excessive accumulation of
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Fig. 7 Feeding inhibited SREBP-2 target sterol biosynthesis genes in a SHP-dependent manner. WT or SHP-KO mice were fasted for 12 h and then
fed or fasted for 6 h and livers were collected. a Levels of phosphorylated ERK and total ERK levels are shown. b Fractionation study: Protein levels
of SHP and SREBP-2 in nuclear and cytoplasmic fractions of mouse liver extracts were measured. c CoIP assays were done to monitor effect of
feeding on interaction with endogenous SHP and SREBP-2. d-f ChIP: Effects of feeding and fasting in WT or SHP-KO mice on (d) gene activation
histone marks at Hmgcr gene, (e) the mRNA levels of indicated genes, and (f) hepatic protein levels of HMGCR. Statistical significance was determined
by the Student’s t-test, (SEM, n = 3-4, *P <0.05, **P <0.01, and NS, statistically not significant). g Mice were fasted for 12 h and then, treated with
GW4064, FGF19, or feeding for 6 h and livers were collected to measure mRNA levels of Hmgcr, Srebp2, and Insig1 genes by q-RTPCR. Statistical
significance was determined by the Student’s t-test, (SEM, n = 5 mice, *P <0.05, **P <0.01)
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genes in the cholesterol biosynthetic and transporter path-
ways, as well as key regulators, were inhibited by FGF19
or feeding, which importantly, was attenuated in SHP-KO
mice, demonstrating a role for SHP in transcriptional in-
hibition of sterol biosynthetic gene networks during the
postprandial period, which provides a potential mechan-
ism for cholesterol-lowering action of FGF15/19 [16]. Our
findings, together with the well-known function of SHP in
suppressing BA biosynthetic genes, identify SHP as a
global transcriptional regulator in maintaining interrelated
cholesterol and BA homeostasis.
Conclusion
Our genome-wide analysis of SHP binding sites in hep-
atic chromatin in mice treated with vehicle or FGF19
reveals unexpectedly that SHP functions as a global
transcriptional partner of SREBP-2 in regulation of sterol
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Fig. 8 Role of FGF19-induced phosphorylation of SHP at Thr-55 in functional interaction with SREBP-2 and inhibition of sterol biosynthetic genes.
a Luciferase reporter assay: HepG2 cells were transfected with the plasmids indicated, treated with FGF19, and luciferase/β-galactosidase activities
were measured. b Experimental outline for adenoviral experiments. c Mice were injected via the tail vein with control Ad-empty, Ad-SHP WT, or
Ad-T55A and then 2 weeks later, livers were collected. For BA feeding (0.5 % CA diet) experiments, mice were fed normal diet (ND) or CA for 6 h
and then, livers were collected. Liver extracts (pooled from n = 3) were prepared and protein levels of SHP, GFP, and actin were detected by IB.
d Mice were injected via the tail vein with adenovirus and 1 week later, the injected mice were treated with vehicle or FGF19 for 2 h and CoIP
assays were done in liver extracts and (e) ChIP assays were done using livers pooled from three mice. f Experimental outline. Mice were injected
with Ad-SHP WT or the T55A mutant, and 2 weeks later, (g) mRNA levels of indicated genes and (h) liver and serum cholesterol levels
were measured
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of the FGF19 pathway has attractive therapeutic poten-
tial for treatment with metabolic disease and bile acid-
related hepatobiliary disorders [16, 29], and in fact,
FGF19 analogs are currently being tested in clinical tri-
als. For this reason, the present study, not only greatly
increases our understanding of the global function of
SHP in mediating FGF19 metabolic action, but also pro-
vides useful information for developing therapeutic strat-
egies for FGF19-associated diseases.
Methods
Reagents
Antibodies for SHP (sc-30169), SREBP-2 (sc-5603),
HDAC1 (sc-7872), HDAC3 (sc-11417), and Lamin A
(sc-20680) were purchased from Santa Cruz Biotechnol-
ogy; for M2 (F3165) from Sigma, for β-actin (#4970)
from Cell Signaling, for LSD1 (ab17721) from Abcam,
and H3K9/K14-Ac (#06-599) and H3K9-me2 (#07-030)
from Millipore. SREBP-2 siRNA (M-050073-01) was
purchased from Dharmacon, Inc., and pcDNA3.1-flag-
SREBP-2 was obtained from Addgene.
Animal experiments
Male C57BL6 mice or SHP-KO mice (8-12 weeks old)
were fasted for 12 h and injected via the tail vein with
vehicle or FGF19 (1 mg/kg) at 09:00, and 2 h or 6 h
later, livers were collected. For adenoviral experiments,
C57BL6 mice were injected via the tail vein with adeno-
viruses (0.5-1.0 × 109 active viral particles in 100 μL PBS)
and 1-2 weeks later, the mice were sacrificed as de-
scribed [12, 13, 30]. For feeding or GW4064 experi-
ments, mice were fasted for 12 h and then, fed for 6 h or
treated with GW4064 (30 mg/kg in corn oil) for 6 h, and
livers were collected for further analyses.
Ethical approval
All animal use and adenoviral protocols were approved
by the Institutional Animal Care and Use and Institutional
Biosafety Committees and were in accordance with
National Institutes of Health guidelines.
ChIP assays and genomic sequencing
Mice were fasted overnight and injected with vehicle or
FGF19, livers were collected 2 h later, and ChIP assays
were performed using SHP antibody (sc-30169). Three
sets of input and immunoprecipitated samples from
three mice were pooled and 18 ng DNA was used for
genomic sequencing using the Illumina/Solexa Genome
Analyzer II (Biotechnology Center, University of Illinois
at Urbana-Champaign). To validate the specificity of the
SHP antibody for ChIP-seq, SHP binding to hepatic
genes was analyzed by three independent ChIP assays
for vehicle- or FGF19-treated WT and SHP-KO mice
(Additional file 1: Figures S1a, S5a).
ChIP-seq mapping and peak finding
The raw ChIP-seq reads were mapped to the mouse






















































Fig. 9 Model: Treatment with FGF19 or physiological activation of FGF15 in mice by feeding increases the interaction between endogenous SHP
and SREBP-2 in the nucleus in the liver and inhibits expression of direct SREBP-2 targets in the sterol biosynthetic genes, in a SHP-dependent
manner. FGF19-induced phosphorylation of SHP at Thr-55 appears to be important for functional interaction with SREBP-2 in the nucleus. Hepatic
genes that have shared binding peaks of SHP and SREBP-2 identified by ChIP-seq, ChIP, or both are indicated in red
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mismatches using Bowtie [31] and peaks were identified
by MACS. Peaks with false discovery rate (FDR) <0.05
were kept. To estimate coverage of our data, a ChIP-seq
saturation test was done by sub-sampling the reads from
all mapped reads. The Pearson correlation coefficient
was calculated for average reads coverage in 10,000 bp
bins across the genome between the sub-sampled data
and the full dataset using the bigwigCorrelate program
from deepTools (version 1.5.11) [32]. We found that the
correlation has reached 0.95 when 75 % of the reads
were sampled. To determine the quality of the ChIP-seq
data, quality metrics from the ENCODE project [33]
were used as benchmarks including: ‘Number of unique
mapped reads’, which was higher than the ENCODE
mean; ‘Signal portion of tags’ (SPOT), with our samples
substantially higher than the ENCODE median; ‘PCR
bottleneck coefficient’, with our samples higher than at
least 25 % of ENCODE data which is considered only ‘mild
bottlenecking’; and ‘normalized strand cross-correlation
coefficient’ and ‘relative strand cross-correlation coeffi-
cient’ which were not high, but mostly above 1 which is
considered acceptable quality by ENCODE.
Data availability
The primary ChIP-Seq data have been deposited to the
NCBI GEO database under the following accession
number, GSE74913.
Peaks annotation and GO analysis
Genomic features associated with peaks were determined
by CEAS [34]. For SHP peaks, the distance to nearest TSS
and enriched GO terms (P value <1e-3, FDR <0.05) were
reported by GREAT version 2.0.2 [35] (association rule:
Single nearest gene: 50 kb max extension and curated
regulatory domains included).
Motif discovery
We used MEME-ChIP [36] for de novo identification of
transcription factor motifs. The regions, +/- 100 bp
centered on peak summits, were extracted and then in-
put to MEME-ChIP. The top 20 motifs (motifs with E-
values <0.05 were considered) with lengths ranging
from 6 to 15 were compared to known motifs in data-
base JASPAR_CORE_2014 [37]. Motifs were also com-
pared with the results from the pipeline ‘peak-motifs’
[38] (motifs with E-values <0.01 were considered)
which were in good agreement with the MEME-ChIP
results (Additional file 2: Table S1).
CoIP, Re-ChIP, and siRNA/ChIP
CoIP and re-ChIP assays were performed as described
[13, 39, 40]. Briefly, in CoIP assays, mouse liver extracts
were prepared in 50 mM Tris-HCl, pH. 8.0, 150 mM NaCl,
2 mM EDTA, 0.5 % NP40, 10 % glycerol. For siRNA/ChIP
assays, hepatocytes were transfected with siRNA and 3 days
later, ChIP assays were done as described [25, 30].
Biochemical fractionation studies
Liver tissues were minced and then resuspended in hypo-
tonic buffer and cells were lysed by homogenization. After
centrifugation, the nuclear pellet and cytoplasmic super-
natant were collected for IB.
GST pull-down assays
DNA fragments containing SREBP-2 (amino acids, 1-480,
1-50, 51-330, and 331-480) were inserted into the
pGEX4T-1 at BamH1/Xho1 sites. GST-fusion proteins
were incubated with the reciprocal proteins that were
synthesized by TNT (Promega, Inc.) and their inter-
action was detected by IB.
Construction of Hmgcr-luc, Insig1-luc, and Srebp2-luc, and
reporter assays
Genomic DNA fragments containing Hmgcr (-190/+65),
Insig-1 (-361/+14), or Srebp-2 (-485/-102), were inserted into
the pGL3-basic-luc plasmid and used for reporter assays.
q-RTPCR
Total RNA was isolated, cDNA was synthesized, and
q-RTPCR was performed and the amount of mRNA
for each gene was normalized to that of 36B4. Primer
sequences used in q-RTPCR and ChIP are listed in
Additional file 2: Table S2.
Additional files
Additional file 1: Figure S1. Information about the quality of SHP
antibody for ChIP and ChIP-seq analysis. Figure S2. Validation of SHP
binding from ChIP-seq analysis. Figure S3. Effects of FGF19 treatment on
SHP binding at hepatic genes. Figure S4. Functional GO analysis of SREBP2
and SHP shared binding sites. Figure S5. Effects of FGF19 on SHP binding
at sterol biosynthetic genes in WT and SHP-KO mice and in primary mouse
hepatocytes. Figure S6. GST-SHP and GST-SREBP2 proteins used in GST
pull-down assay. (PDF 801 kb)
Additional file 2: Table S1. Comparison between MEME-ChIP and
peak-motifs on predicting interacting TFs. Table S2. Primer sequences
used in q-RTPCR and ChIP studies. (PDF 14 kb)
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